Odonate Future Growth
Future criteria checks 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Odonate.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 21.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09Odonate Therapeutics: Lessons Learned
Apr 27We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Revisiting Odonate Therapeutics
Feb 01Odonate: A Simple Story Of An Oral Taxane
Jan 10Odonate Therapeutics: Likely Tesetaxel Approval Means Company Is Undervalued
Jan 08Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares
Jan 07Odonate CEO buys $4.2M shares
Dec 24Odonate announces positive Phase 3 data in metastatic breast cancer
Dec 11Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
Dec 09
Odonate Therapeutics EPS in-line
Oct 28In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Odonate has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2021 | N/A | -102 | -95 | -95 | N/A |
| 6/30/2021 | N/A | -119 | -105 | -105 | N/A |
| 3/31/2021 | N/A | -130 | -111 | -110 | N/A |
| 12/31/2020 | N/A | -126 | -114 | -113 | N/A |
| 9/30/2020 | N/A | -122 | -107 | -106 | N/A |
| 6/30/2020 | N/A | -118 | -103 | -103 | N/A |
| 3/31/2020 | N/A | -113 | -98 | -97 | N/A |
| 12/31/2019 | N/A | -112 | -97 | -97 | N/A |
| 9/30/2019 | N/A | -113 | -94 | -94 | N/A |
| 6/30/2019 | N/A | -110 | -89 | -88 | N/A |
| 3/31/2019 | N/A | -101 | -84 | -82 | N/A |
| 12/31/2018 | N/A | -89 | -69 | -67 | N/A |
| 9/30/2018 | N/A | -76 | -61 | -59 | N/A |
| 6/30/2018 | N/A | -62 | -52 | -51 | N/A |
| 3/31/2018 | N/A | -47 | -37 | -37 | N/A |
| 12/31/2017 | N/A | -33 | -26 | -26 | N/A |
| 9/30/2017 | N/A | -19 | -13 | -13 | N/A |
| 6/30/2017 | N/A | -10 | -6 | -6 | N/A |
| 3/31/2017 | N/A | -6 | -3 | -3 | N/A |
| 12/31/2016 | N/A | -3 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ODTC es superior a la tasa de ahorro (2.2%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de ODTC crezcan más deprisa que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ODTC crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ODTC crezcan más rápido que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de ODTC crezcan a un ritmo superior a 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de ODTC se prevé elevada dentro de 3 años.